News / Announcements
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real-World Opportunistic Study
Poster 0384: November 16, 2024, 10:30 AM – 12:30 PM, Poster Session A, Pediatric Rheumatology – Clinical Poster I
Efficacy and Safety of Tofacitinib in Patients with Systemic Juvenile Idiopathic Arthritis
Poster L09: November 18, 2024, 10:30 AM – 12:30 PM, Poster Session C, (L01-L14) Late Breaking Posters
AbbVie has recently received FDA approval for Upadacitinib as a twice-daily liquid or once-daily pill in children 2+ years with active pJIA and in children 2 to less than 18 years with active psoriatic arthritis when TNF blockers did not work well or could not be tolerated.
Click here to view the AbbVie press release.
September 13, 2024: UCB received FDA approval for Cimzia (certolizumab pegol) in polyarticular JIA in patients 2 years of age and older.
20-May-2024: GSK received FDA approval for Benlysta Autoinjector for Children with SLE. Click here to view the GSK press release.